CN102617612A - 比阿培南b型结晶 - Google Patents
比阿培南b型结晶 Download PDFInfo
- Publication number
- CN102617612A CN102617612A CN2011100365971A CN201110036597A CN102617612A CN 102617612 A CN102617612 A CN 102617612A CN 2011100365971 A CN2011100365971 A CN 2011100365971A CN 201110036597 A CN201110036597 A CN 201110036597A CN 102617612 A CN102617612 A CN 102617612A
- Authority
- CN
- China
- Prior art keywords
- biapenem
- crystallization
- type
- crystal composition
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 title claims abstract description 50
- 229960003169 biapenem Drugs 0.000 title claims abstract description 50
- 239000013078 crystal Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000001228 spectrum Methods 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000002425 crystallisation Methods 0.000 claims description 32
- 230000008025 crystallization Effects 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 241000186046 Actinomyces Species 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000588914 Enterobacter Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000605909 Fusobacterium Species 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588621 Moraxella Species 0.000 claims description 2
- 241000191992 Peptostreptococcus Species 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 2
- 241001148470 aerobic bacillus Species 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 6
- 239000013557 residual solvent Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910017488 Cu K Inorganic materials 0.000 description 2
- 229910017541 Cu-K Inorganic materials 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OTTZHAVKAVGASB-UHFFFAOYSA-N hept-2-ene Chemical compound CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- YKMONJZIUAOVEM-WDSKDSINSA-N 1beta-methylcarbapenem Chemical compound C[C@H]1C=CN2C(=O)C[C@@H]12 YKMONJZIUAOVEM-WDSKDSINSA-N 0.000 description 1
- BSHRJMFSUUNQRJ-MZVJPFDCSA-N 6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound CC1C=C(C(O)=O)N2C(=O)C([C@H](O)C)C21 BSHRJMFSUUNQRJ-MZVJPFDCSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100365971A CN102617612B (zh) | 2011-01-29 | 2011-01-29 | 比阿培南b型结晶 |
CN201310221303.1A CN103497207B (zh) | 2011-01-29 | 2011-01-29 | 比阿培南b型结晶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100365971A CN102617612B (zh) | 2011-01-29 | 2011-01-29 | 比阿培南b型结晶 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310221303.1A Division CN103497207B (zh) | 2011-01-29 | 2011-01-29 | 比阿培南b型结晶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102617612A true CN102617612A (zh) | 2012-08-01 |
CN102617612B CN102617612B (zh) | 2013-07-17 |
Family
ID=46557866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100365971A Active CN102617612B (zh) | 2011-01-29 | 2011-01-29 | 比阿培南b型结晶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102617612B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159789A (zh) * | 2011-12-16 | 2013-06-19 | 四川科伦药物研究有限公司 | 一种比阿培南结晶体及其制备方法 |
CN113912629A (zh) * | 2021-11-01 | 2022-01-11 | 石药集团中诺药业(石家庄)有限公司 | 一种比阿培南的结晶方法 |
CN114349772A (zh) * | 2020-10-13 | 2022-04-15 | 珠海联邦制药股份有限公司 | 一种比阿培南粗品的精制方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101007816A (zh) * | 2006-01-26 | 2007-08-01 | 江苏先声药物研究有限公司 | 一种改进的比阿培南的制备方法 |
CN201007816Y (zh) * | 2006-12-30 | 2008-01-16 | 曙光信息产业(北京)有限公司 | 一种刀片服务器散热机箱 |
CN101121716A (zh) * | 2007-09-28 | 2008-02-13 | 严洁 | 一种比阿培南的合成方法 |
CN101805359A (zh) * | 2010-04-10 | 2010-08-18 | 浙江华海药业股份有限公司 | 一种制备高纯度比阿培南的方法 |
CN102617611A (zh) * | 2011-01-28 | 2012-08-01 | 江苏正大天晴药业股份有限公司 | 比阿培南无菌粉的制备方法 |
-
2011
- 2011-01-29 CN CN2011100365971A patent/CN102617612B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101007816A (zh) * | 2006-01-26 | 2007-08-01 | 江苏先声药物研究有限公司 | 一种改进的比阿培南的制备方法 |
CN201007816Y (zh) * | 2006-12-30 | 2008-01-16 | 曙光信息产业(北京)有限公司 | 一种刀片服务器散热机箱 |
CN101121716A (zh) * | 2007-09-28 | 2008-02-13 | 严洁 | 一种比阿培南的合成方法 |
CN101805359A (zh) * | 2010-04-10 | 2010-08-18 | 浙江华海药业股份有限公司 | 一种制备高纯度比阿培南的方法 |
CN102617611A (zh) * | 2011-01-28 | 2012-08-01 | 江苏正大天晴药业股份有限公司 | 比阿培南无菌粉的制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103159789A (zh) * | 2011-12-16 | 2013-06-19 | 四川科伦药物研究有限公司 | 一种比阿培南结晶体及其制备方法 |
CN103159789B (zh) * | 2011-12-16 | 2015-11-25 | 四川科伦药物研究有限公司 | 一种比阿培南结晶体及其制备方法 |
CN114349772A (zh) * | 2020-10-13 | 2022-04-15 | 珠海联邦制药股份有限公司 | 一种比阿培南粗品的精制方法 |
CN114349772B (zh) * | 2020-10-13 | 2022-11-25 | 珠海联邦制药股份有限公司 | 一种比阿培南粗品的精制方法 |
CN113912629A (zh) * | 2021-11-01 | 2022-01-11 | 石药集团中诺药业(石家庄)有限公司 | 一种比阿培南的结晶方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102617612B (zh) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1061348C (zh) | 一种喹啉羧酸盐酸盐的新结晶型体及其制法和药物制剂 | |
AU2016240841C1 (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
TW201141867A (en) | Improved process for the preparation of carbapenem using carbapenem intermediates and recovery of carbapenem | |
CN100360530C (zh) | 结晶性1-甲基碳青霉烯化合物 | |
ES2746045T3 (es) | Forma cristalina de ertapenem de sodio y método de preparación para la misma | |
CN102924483B (zh) | 一种头孢他啶晶体化合物、其制备方法及其无菌混合粉形式的药物组合物 | |
CN102363617B (zh) | 一种厄他培南单钠盐结晶体及其制备方法 | |
CN102558181B (zh) | 一种碳青霉烯抗生素的制备方法 | |
AU2011240493A1 (en) | Purification method of azacyclohexapeptide or its salt | |
CN102268018A (zh) | 头孢克肟的结晶方法 | |
MX2011009532A (es) | Metodo mejorado para preparar meropenem usando polvo de zinc. | |
WO2013029293A1 (zh) | 一种制备厄他培南钠的方法 | |
CN102617612B (zh) | 比阿培南b型结晶 | |
RU2009119411A (ru) | Новые кристаллические формы | |
JP2011504495A (ja) | 2−アリールメチルアゼチジン−カルバペネム−3−カルボン酸エステル誘導体またはその塩、その製造方法及びそれを含む医薬組成物 | |
WO2007104219A1 (en) | A process for the preparation of the intermediate of β-methyl carbapenem | |
CN102268024B (zh) | 比阿培南新晶型及其合成方法 | |
CN1432016A (zh) | 吡咯烷硫卡培南衍生物的新型结晶 | |
Kawamoto et al. | Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety | |
KR20110114549A (ko) | 니코우사미드 화합물의 5가지 결정형, 이의 제조방법, 약물 조합물 및 용도 | |
JP7213173B2 (ja) | カルバペネム化合物 | |
CN102977101A (zh) | 多尼培南一水合物、其药物组合物、其制备方法和用途 | |
CN101100469B (zh) | 多尼培南的新结晶及其制备方法和用途 | |
CN103497207B (zh) | 比阿培南b型结晶 | |
CN112079819B (zh) | 一种改进的伏立康唑消旋体制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170621 Address after: 222069 Golden Bridge in Jiangsu province Lianyungang City Economic and Technological Development Zone Dapu Industrial Zone, Road No. 16 Patentee after: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |